Department of Nuclear Medicine, Cardiac Imaging, University and University Hospital Zurich, NUK A 12 Ramistrasse 100, 8091, Zurich, Switzerland.
Int J Cardiovasc Imaging. 2024 Oct;40(10):2203-2212. doi: 10.1007/s10554-024-03212-w. Epub 2024 Aug 5.
This study aimed to evaluate the impact of acute intravenous beta-blocker administration on myocardial blood flow (MBF) during same-day hybrid coronary computed tomography angiography (CCTA) and 13N-ammonia positron emission tomography (PET) myocardial perfusion imaging (MPI). Previous research on the discontinuation of oral beta-blockers before MPI has shown mixed results, with no studies yet exploring the acute intravenous administration in the context of same-day hybrid imaging. This retrospective study included patients with suspected chronic coronary syndromes undergoing same-day hybrid CCTA/13N-ammonia PET MPI. Exclusion criteria comprised coronary artery stenosis ≥ 50% or regional perfusion abnormalities on PET, and baseline oral beta-blocker medication. Intravenous metoprolol (up to 30 mg) was administered as needed for heart rate control before CCTA. MBF measurements were obtained at rest (rMBF) and during stress (sMBF), and myocardial flow reserve (MFR) was calculated. After excluding 281 patients, 154 were eligible for propensity-score matching, resulting in 108 patients divided into two equal groups based on beta-blocker administration. The groups showed no significant differences in baseline characteristics. Among those who received beta-blockers, there was a significant decrease in sMBF (2.21 [IQR 1.72-2.78] versus 2.46 [2.08-2.99] ml∙min∙g, p = 0.027) and MFR (3.46 [2.70-4.05] versus 3.79 [3.22-4.46], p = 0.030), respectively, compared to those who did not receive beta-blockers. In contrast, rMBF remained unaffected (0.65 [0.54-0.78] versus 0.64 [0.55-0.76] ml∙min∙g, p = 0.931). Acute intravenous beta-blocker administration significantly impacts MBF, leading to a slight reduction in sMBF and MFR. In contrast, rMBF appears unaffected, suggesting that beta-blockers primarily affect the coronary capacity to respond to vasodilators.
本研究旨在评估同日行杂交式冠状动脉计算机断层扫描血管造影术(CCTA)和 13N-氨正电子发射断层扫描(PET)心肌灌注成像(MPI)期间急性静脉内β受体阻滞剂给药对心肌血流(MBF)的影响。先前关于 MPI 前停用口服β受体阻滞剂的研究结果不一,尚无研究探讨同日行杂交式成像时的急性静脉内给药。这项回顾性研究纳入了同日行杂交式 CCTA/13N-氨 PET MPI 检查的疑似慢性冠状动脉综合征患者。排除标准包括冠状动脉狭窄≥50%或 PET 上存在区域性灌注异常,以及基线口服β受体阻滞剂治疗。CCTA 前按需给予静脉注射美托洛尔(最高 30mg)以控制心率。在静息时(rMBF)和应激时(sMBF)获得 MBF 测量值,并计算心肌血流储备(MFR)。排除 281 例患者后,154 例符合倾向评分匹配条件,其中 108 例患者按β受体阻滞剂给药情况分为两组,每组 54 例。两组患者的基线特征无显著差异。在接受β受体阻滞剂治疗的患者中,sMBF(2.21[IQR 1.72-2.78]与 2.46[2.08-2.99]ml∙min∙g,p=0.027)和 MFR(3.46[2.70-4.05]与 3.79[3.22-4.46],p=0.030)分别显著下降,而 rMBF 无显著变化(0.65[0.54-0.78]与 0.64[0.55-0.76]ml∙min∙g,p=0.931)。急性静脉内β受体阻滞剂给药显著影响 MBF,导致 sMBF 和 MFR 略有降低。相反,rMBF 似乎不受影响,表明β受体阻滞剂主要影响冠状动脉对血管扩张剂的反应能力。